大肠癌肿瘤组织中p16基因异常甲基化检测

采用甲基化特异PCR技术 (MSP法 )检测大肠癌患者肿瘤组织中p16基因启动子区异常甲基化改变情况 ,探讨其与大肠癌发生、发展和临床资料的关系。结果显示 ,13例标本 ( 40 .6% )呈p16甲基化阳性 ;DukesC、D期病人肿瘤组织中p16甲基化发生率 ( 63 % )明显高于DukesA、B期病人 ( 2 5 % ) ;在病理分期中 ,高、中分化癌中的p16甲基化阳性率( 3 0 % )低于低分化癌的阳性率 ( 10 0 % ) ;具淋巴结转移癌患者肿瘤组织中p16基因甲基化的阳性率( 63 % )高于淋巴结未转移的阳性率 ( 2 5 % )。研究表明 ,p16甲基化与大肠癌的发生发展和转移呈一定相关性 ,p16甲基化有可能作为大肠癌病人诊断、判断预后的候选标志物之一

STUDY OF ABERRANT METHYLATION OF p16 GENE IN PATIENTS WITH COLORECTAL CANCER

To explore whether aberrant methylation in the promoter of p16 gene was associated with development and clinicopathological characteristics of colorectal cancer. Methylation-specific PCR(MSP) was used to detect hypermethylation of p16 gene in tumor tissues obtained from 32 patients with colorectal cancer. The results showed that the hypermethylation of p16 promoter was detected in 40.6% of tumor tissues. p16 hypermethylation in patients with Dukes stages of C and D tumors (63%) was higher than that in the stages of A and B tumors (25%). The highly and intermediately differentiated carcinomas had lower positive rate (30%) than the poorly differentiated carcinoma. Furthermore, the hypermethylation of p16 gene in tumor tissue from patients with the lymph node metastasis was different from that without lymph node metastasis (P<0.05). The results suggested that p16 hypermethylation was associated with the development of colorectal cancer and its metastatic potency, and it could be used as a putative prognostic indicator for this malignancy.